AIM
KRSA

Alambic Investment Management’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Alambic Investment Management’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-74
Closed -$63K – 14
2020
Q3 		$63K Sell
74
-76
-51% -$60.8K 0.69% 51
2020
Q2 		$124K Sell
150
-2
-1% -$1.17K 0.31% 120
2020
Q1 		$56K Sell
152
-164
-52% -$81.9K 0.14% 160
2019
Q4 		$120K Buy
+316
New +$207K 0.1% 237

Other funds holding KRSA

Slate Path Capital
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Alambic Investment Management's KRSA Position: Q4 2020 in Review

Alambic Investment Management sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2020, closing a stake of 74 shares — an estimated $63K sold.

Alambic Investment Management first reported a position in KRSA in Q4 2019 and held it in 4 quarters. The position peaked at $124K in Q2 2020. 70 funds tracked by Wall St. Rank hold KRSA as of Q4 2020.

  • Alambic Investment Management reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Alambic Investment Management sold 74 Korsana Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $63K.
  • Alambic Investment Management first reported a position in Korsana Biosciences, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Alambic Investment Management's Korsana Biosciences, Inc. Common Stock position peaked at $124K in Q2 2020.
  • 70 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2020.

Based on Alambic Investment Management's 13F filing for Q4 2020.